urban-gro, Inc.

United States / AgTech Primary: Nasdaq Secondary: Frankfurt Stock Exchange Bloomberg: UGRO US ISIN: US91704K2024 Cannabis rescheduling & Q1 results

RATING PRICE TARGET	BUY \$ 4.30
Return Potential	131.2%
Risk Rating	High

HIGH TIMES FOR U.S. CANNABIS

After months of rumours and market speculation, news broke Tuesday that the DEA (Drug Enforcement Administration) is finally set to sign off on cannabis rescheduling. This historic shift in Federal policy was confirmed by multiple sources close to the situation and sent cannabis stocks soaring. The move to a Schedule 3 drug will result in massive tax savings for cannabis operators, which should in turn stimulate investment across the sector. The news overshadowed UG's Q1 reporting, which showed good sequential improvement, and importantly, hit guidance for the period. Management confirmed their full year targets calling for \$84m in sales and a break even AEBITDA. The confirmed guide does not reflect rescheduling. UG will undoubtedly benefit from the loosened restrictions, but it may take months to wrap up the legal process before the upside crystallises. That said, we should see a more stable shift in sector sentiment straight away. We are Buy-rated on UGRO with an unchanged \$4.3 TP.

High times for U.S. cannabis The DEA is now expected to nod through the most significant cannabis reform since weed was banned in 1970. Pot will become a Schedule 3 drug (now: Schedule 1), which will allow cannabis operators to bypass punitive tax codes. Currently, the IRS code known as 280E prevents companies trafficking in Schedule 1 substances from writing off expenses on their federal tax returns, meaning any expense unrelated to cost of goods sold is non-deductible. The elimination of the 280E roadblock will clear the way for weed operators to redirect the tax savings into investment for facilities and equipment. While the industry-wide tax windfall won't be captured all at once, we do expect earnings and operating cash flows to start improving incrementally later this year. This is good news for UG and will certainly jumpstart its stagnating high-margin Equipment Systems and Services segments.

Rescheduling could also influence other policy Aside from the aforementioned tax benefits, the shift in Federal policy may help prod other policymakers and voters. Rescheduling could boost support for. . . (p.t.o.)

FINANCIAL HISTORY & PROJECTIONS

	2020	2021	2022	2023	2024E	2025E
Revenue (\$m)	25.84	62.11	67.03	71.54	82.87	115.29
Y-o-y growth	6.8%	140.4%	7.9%	6.7%	15.8%	39.1%
AEBITDA (\$m)	-0.65	2.68	-3.89	-9.71	0.59	2.20
AEBITDA margin	-2.5%	4.3%	-5.8%	-13.6%	0.7%	1.9%
Net income (\$m)	-5.07	-0.88	-15.28	-18.68	-5.36	-2.86
EPS (diluted) (\$)	-1.06	-0.09	-1.44	-1.66	-0.44	-0.29
DPS (\$)	0.00	0.00	0.00	0.00	0.00	0.00
FCF (\$m)	-3.81	-9.90	-17.06	-9.21	0.42	0.22
Net gearing	-83.7%	-71.8%	-23.5%	10.4%	7.6%	10.7%
Liquid assets (\$m)	0.18	34.59	12.01	1.11	1.33	1.37

* adjusted EBITDA

RISKS

Risks include but aren't limited to regulatory, financing and market cyclicality, particularly in the cannabis sector.

COMPANY PROFILE

urban-gro, Inc is a provider of professional turnkey facility services to the CEA (Controlled Environment Agriculture) industry and various commercial sectors. Headquartered in Denver, Colorado, the company now operates six offices across North America and one in Europe. Urban-gro has 140 employees.

MARKET DA	As of 01 May 2024				
Closing Price	\$ 1.86				
Shares outstand	12.07m				
Market Capitalis	:	\$ 22.46m			
52-week Range	\$ 1.00 / 2.82				
Avg. Volume (12		105,302			
Multiples	2023	2024E	2025E		
P/E	n.a.	n.a.	n.a.		
EV/Sales	0.3	0.3	0.2		
EV/EBITDA	n.a.	40.8	11.0		

STOCK OVERVIEW



COMPANY DATA	As of 31 Mar 2024
Liquid Assets	\$ 0.70m
Current Assets	\$ 33.20m
Intangible Assets	\$ 4.20m
Total Assets	\$ 56.13m
Current Liabilities	\$ 35.48m
Shareholders' Equity	\$ 18.59m
SHAREHOLDERS	
Insiders	28.9%
Institutional Holdings	28.0%
Free Float	43.1%

... the SAFER Banking Act (see note of 27 September 2023), which is still working through the legal process. Plus, recreational marijuana will go before Florida voters this November, but the amendment would have to receive a supermajority or 60% of the vote to be passed. Florida would then become the 25th state to legalise marijuana usage for recreational fun alongside medical purposes.

Next steps in the rescheduling process The New York Times reported that Attorney General Merrick Garland was expected to make the rescheduling recommendation to the White House Office of Management and Budget (OMB) on Tuesday, Once reviewed by the White House, the rescheduling proposal will go back to the Justice Department, which will publish a proposed rule in the Federal Register. A public comment period will ensue, along with hearings in front of an administrative law judge, before the rule can become law.

Market watchers caution that proposed rescheduling will almost certainly draw lawsuits, which could drag out the process. The OMB could sit with the decision for as long as three months, while the comment period could also take months. Regardless of the timeline, there is no putting the genie back in the bottle.

We suspect cannabis operators will look to move ahead as quickly as possible with pent up expansion plans. This should lead to discussions with vendors and service providers, such as urban-gro. We will reassess our forecasts, once the rescheduling timeline becomes clearer.

FIRST QUARTER HIGHLIGHTS

Table 1: First quarter results vs FBe and prior year

All figures in USDm	Q1/24	Q1/24E	variance	Q1/23	variance
Revenue	15.5	15.2	2%	16.8	-8%
Gross profit	3.1	2.4	31%	2.8	11%
Margin	20.0%	15.5%	-	16.7%	-
AEBITDA	-0.3	-0.5	-	-3.4	-
Margin	-	-	-	-	-

Source: First Berlin Equity Research; urban-gro

Sequential improvements urban-gro notched roughly \$15.5m in revenues for the quarter, which was in line with our target. The 4% Q/Q uptick in sales owes to a \$0.6m rise in Services revenue and a \$0.4m increase in Equipment Systems turnover. This was partially negated by a \$0.4m decline in Construction Design-build sales (table 2).

All figures in USDm	Q1/24	Q1/24E	variance	Q1/23	variance
Equipment systems	2.5	2.2	14%	2.9	-14%
Services	3.1	2.6	19%	3.5	-11%
Construction Design-build	9.8	10.2	-4%	10.2	-4%
Other	0.1	0.2	-50%	0.2	-50%
Total revenue	15.5	15.2	2%	16.8	-8%

Table 2: Revenue by segment

Source: First Berlin Equity Research; urban-gro

AEBITDA loss pared down to \$-0.3m Gross profit increased to \$3.1m equal to a 20% margin and topped the prior year comp of \$1.7m thanks to margin expansion to 52% for the Services segment (2024: 39%). The showing reflects improved productivity by UGRO's architects and engineers alongside increased construction margins. Operating expenses were trimmed down to \$5.2m vs \$6.4m in the October-to-December period and equated to 33% of sales (Q4/23: 42%). The sequential decrease stems from the ~\$8m in cost cutting measures communicated in H2/23.

Table 3: Updated order backlog

1			
	-	1	1%
2	3	5	5%
72	21	93	85%
75	24	99	90%
76%	24%	100%	
	72 75	72 21 75 24	72 21 93 75 24 99

Source: First Berlin Equity Research; urban-gro

The order backlog stood at \$99m (table 3) giving the company good visibility to meet its full year revenue target of \$84m. Commercial projects for the Construction design-build segment were converted to sales leading to a 10% sequential decline in the backlog, but, with a number of new projects in the discussion phase we do not expect this to dip further.




Figure 1: Order backlog developments

Source: First Berlin Equity Research; urban-gro

Table 4: Financial highlights

Q1/24	2023	variance
0.7	1.1	-36%
2.5	3.2	-22%
1.8	2.1	-14%
56.1	64.4	-13%
18.6	20.1	-7%
33%	31%	-
	0.7 2.5 1.8 56.1 18.6	0.7 1.1 2.5 3.2 1.8 2.1 56.1 64.4 18.6 20.1

Source: First Berlin Equity Research; urban-gro

urban-gro exited the quarter with cash and liquid assets of \$0.7m vs \$1.1m at the end of 2023. The 36% Q/Q drop-off stems from a decrease in contract liabilities traced to billing timing of construction projects. The company has only drawn down around \$2m of its RCF and will continue to lean on this to cover working capital when needed. UG's financial boss, Dick Akright, reiterated on the earnings call that the company does not need to consider a cap hike.

It should also be noted that a pickup in Equipment Systems sales will help ease WC needs, since orders are coupled with deposits. Segment activity has been at rock bottom levels, but will likely be the first to benefit from the rescheduling.

			upside	aiviaena yiera	total return
4.3	4.3	0%	131%	0.0%	131%
	2024E			2025E	
old	new	revision	old	new	revision
82,503	82,870	0.4%	114,784	115,290	0.4%
12,075	12,826	6.2%	17,215	17,496	1.6%
14.6%	15.5%	-	15.0%	15.2%	-
242	595	145.7%	1,998	2,203	10.3%
0.3%	0.7%	-	1.7%	1.9%	-
	old 82,503 12,075 14.6% 242	2024E old new 82,503 82,870 12,075 12,826 14.6% 15.5% 242 595	2024E old new revision 82,503 82,870 0.4% 12,075 12,826 6.2% 14.6% 15.5% - 242 595 145.7%	2024E revision old old new revision old 82,503 82,870 0.4% 114,784 12,075 12,826 6.2% 17,215 14.6% 15.5% - 15.0% 242 595 145.7% 1,998	2024E 2025E old new revision old new 82,503 82,870 0.4% 114,784 115,290 12,075 12,826 6.2% 17,215 17,496 14.6% 15.5% - 15.0% 15.2% 242 595 145.7% 1,998 2,203

Table 5: Changes to FBe and TP

Source: First Berlin Equity Research estimates

Maintaining Buy rating and \$4.3 TP Updated forecasts factor in first quarter results leading to only minor changes. We will wait for the discussed rescheduling process to play out before fully reassessing our estimates and target price. That said we see upside to confirmed revenue guidance of \$84m, which does account for the expected upswing in cannabis.

VALUATION MODEL

Table 6: DCF model

In USD '000			2024E	2025E	2026E	2027E	2028E	2029E	2030E	20311
Sales			82,870	115,290	146,419	178,631	208,998	234,078	257,485	280,65
NOPLAT			-5,157	-2,679	256	3,463	7,493	9,111	10,768	12,50
(+) depreciation & amortisation			580	576	586	536	627	632	630	625
Net operating cash flow			-4,577	-2,103	842	3,999	8,120	9,743	11,397	13,132
(-) Total investments (CAPEX and WC)			-137	-1,119	-1,953	-1,887	-2,093	-1,385	-1,414	-1,480
(-) Capital expenditures			-671	-703	-747	-732	-648	-726	-798	-870
(-) Working capital			534	-416	-1,206	-1,154	-1,445	-660	-616	-609
Free cash flows (FCF)			-4,714	-3,222	-1,111	2,112	6,028	8,357	9,983	11,652
PV of FCF's			-4,319	-2,587	-782	1,303	3,260	3,963	4,150	4,246
				Terminal EBIT margin						
In EUR '000				5.8%	6.3%	6.8%	7.3%	7.8%	8.3%	8.8%
PV of FCFs in explicit period	24,256		11.1%	5.6	6.0	6.5	7.0	7.4	7.9	8.4
(+) PV of FCFs in terminal period	29,664	0	12.1%	4.8	5.1	5.5	5.9	6.2	6.6	7.0
Enterprise value (EV)	53,920	WACC	13.1%	4.1	4.4	4.7	5.0	5.3	5.6	5.9
(+) Net cash / (-) net debt	-2,092	\$	14.1%	3.5	3.8	4.0	4.3	4.5	4.8	5.0
(+) Investments / minority interests	0		15.1%	3.1	3.3	3.5	3.7	3.9	4.1	4.3
Shareholder value	51,828		16.1%	2.7	2.9	3.0	3.2	3.4	3.6	3.7
Fair value per share (\$)	4.3		17.1%	2.4	2.5	2.7	2.8	3.0	3.1	3.3
						Terminal gro	wth rate			
				1.0%	1.5%	2.0%	2.5%	3.0%	3.5%	4.0%
Cost of equity	15.5%		11.1%	6.2	6.5	6.7	7.0	7.3	7.6	8.0
Pre-tax cost of debt	9.0%	U I	12.1%	5.3	5.5	5.7	5.9	6.1	6.3	6.6
Tax rate	30.0%	WACC	13.1%	4.6	4.7	4.9	5.0	5.2	5.3	5.5
After-tax cost of debt	6.3%	3	14.1%	4.0	4.1	4.2	4.3	4.4	4.6	4.7
Share of equity capital	85.0%		15.1%	3.5	3.5	3.6	3.7	3.8	3.9	4.0
Share of debt capital	15.0%		16.1%	3.0	3.1	3.2	3.2	3.3	3.4	3.5
WACC	14.1%		17.1%	2.7	2.7	2.8	2.8	2.9	2.9	3.0

INCOME STATEMENT

All figures in USD '000	2020	2021	2022	2023	2024E	2025E
Revenues	25,838	62,113	67,030	71,543	82,870	115,290
Cost of goods sold	-20,122	-47,353	-52,824	-61,251	-70,045	-97,794
Gross profit	5,716	14,760	14,206	10,292	12,826	17,496
SG&A	-6,658	-13,124	-24,271	-24,770	-15,911	-17,870
Stock-based compensation	-1,803	-1,841	-2,572	-2,199	-2,072	-2,306
Operating income (EBIT)	-2,746	-205	-12,637	-16,677	-5,157	-2,679
Net financial result	-1,498	-334	274	-98	-200	-180
Other non-operating result	-831	-337	-577	-1,863	0	0
Impairment loss	0	0	-2,661	-259	0	0
Pre-tax income (EBT)	-5,074	-876	-15,600	-18,897	-5,357	-2,859
Income taxes	0	0	322	216	0	0
Minority interests	0	0	0	0	0	0
Net income / loss	-5,074	-876	-15,278	-18,681	-5,357	-2,859
Diluted EPS (in \$)	-1.06	-0.09	-1.44	-1.66	-0.44	-0.29
AEBITDA	-652	2,679	-3,888	-9,712	595	2,203
Ratios						
Gross margin	22.1%	23.8%	21.2%	14.4%	15.5%	15.2%
EBIT margin	-10.6%	-0.3%	-18.9%	-23.3%	-6.2%	-2.3%
AEBITDA margin	-2.5%	4.3%	-5.8%	-13.6%	0.7%	1.9%
Net margin	-19.6%	-1.4%	-22.8%	-26.1%	-6.5%	-2.5%
Tax rate	15.0%	21.0%	21.0%	21.0%	21.0%	21.0%
Expenses as % of revenues						
SG&A	25.8%	21.1%	36.2%	34.6%	19.2%	15.5%
Stock-based compensation	7.0%	3.0%	3.8%	3.1%	2.5%	2.0%
Y-Y Growth						
Revenues	6.8%	140.4%	7.9%	6.7%	15.8%	39.1%
Operating income	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.
Net income/ loss	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.

BALANCE SHEET

All figures in USD '000	2020	2021	2022	2023	2024E	2025E
Assets						
Current assets, total	5,245	59,480	34,558	40,952	29,341	36,705
Cash and equivalents	185	34,591	12,008	1,113	1,330	1,370
Trade receivables	915	13,126	15,380	26,992	18,163	25,269
Inventories	537	515	320	229	384	536
Other ST assets	3,609	11,248	6,849	12,618	9,464	9,530
Non-current assets, total	2,915	14,675	27,508	23,427	23,539	23,686
Property, plant & equipment	129	208	1,307	1,419	1,428	1,439
Goodw ill & other intangibles	991	9,568	21,023	19,967	20,049	20,165
Financial assets	1,710	4,210	2,559	0	0	0
Other LT assets	85	690	2,619	2,041	2,062	2,082
Total assets	8,161	74,155	62,066	64,379	52,880	60,391
Shareholders' equity & debt						
Current liabilities, total	14,546	25,005	24,256	42,110	33,800	41,765
Trade payables	654	6,067	9,960	25,411	17,271	24,114
ST debt	5,360	0	3,833	3,205	2,600	3,100
Customer deposits	4,879	13,345	2,571	603	698	972
Provisions	1,799	3,878	3,197	4,071	4,234	4,403
Other current liabilities	1,855	1,716	4,695	8,820	8,997	9,176
Long-term liabilities, total	1,021	983	3,078	2,198	2,294	2,394
Long-term debt	1,021	0	0	0	0	0
Deferred tax liabilities	0	441	1,033	817	858	901
Other non-current liabilities	0	542	2,045	1,380	1,436	1,493
Shareholders' equity	-7,406	48,167	34,732	20,071	16,786	16,232
Total consolidated equity and debt	8,161	74,155	62,066	64,379	52,880	60,391
Ratios						
Current ratio (x)	0.4	2.4	1.4	1.0	0.9	0.9
Quick ratio (x)	0.3	2.4	1.4	1.0	0.9	0.9
Equity ratio	-91%	65%	56%	31%	32%	27%
Net debt	6,197	-34,591	-8,175	2,092	1,270	1,730
Net debt / EBITDA (x)	-9.5	-12.9	2.1	-0.2	2.1	0.8
Net gearing	-84%	-72%	-24%	10%	8%	11%
Return on equity (ROE)	69%	-2%	-44%	-93%	-32%	-18%
Capital employed (CE)	1,016	9,357	12,498	7,624	7,181	7,723
Return on capital employed (ROCE)	-270%	1%	-93%	-205%	-64%	-27%

CASH FLOW STATEMENT

All figures in USD '000	2020	2021	2022	2023	2024E	2025E
Net income	-5,074	-876	-15,278	-18,681	-5,357	-2,859
Depreciation and amortisation	258	495	1,483	1,637	580	576
Amortisation of financing instruments	558	104	0	0	0	0
Stock-based compensation	1,803	1,841	2,572	2,199	2,072	2,306
Other non-cash items	1,016	500	3,427	1,155	0	0
Tax result	0	0	-322	-216	0	0
Net interest expense	0	0	-274	98	200	180
Operating cash flow	-1,438	2,064	-8,393	-13,808	-2,505	203
Change in w orking capital	-2,195	-3,628	-4,220	2,714	3,594	721
Tax paid	0	0	0	0	0	0
Net operating cash flow	-3,633	-1,564	-12,613	-11,094	1,088	923
Cash flow from investing	-176	-8,337	-4,452	1,885	-671	-703
Free cash flow (FCF)	-3,809	-9,901	-17,065	-9,209	417	220
Equity inflow, net	0	57,747	30	0	0	0
Debt inflow, net	4,183	-5,756	0	-758	0	0
Interest expenses paid	-638	0	0	-272	-200	-180
Stock buyback	0	-7,684	-4,362	0	0	0
Other adjustments	0	0	-1,186	-656	0	0
Cash flow from financing	3,545	44,308	-5,518	-1,686	-200	-180
Net cash flows	-264	34,407	-22,583	-10,895	217	40
Cash, start of the year	449	184	34,591	12,008	1,113	1,330
Cash, end of the year	184	34,591	12,008	1,113	1,330	1,370
EBITDA/share (in \$)	-0.14	0.27	-0.37	-0.86	0.05	0.22
Y-Y Growth						
Operating cash flow	n.m.	n.m.	n.m.	n.m.	n.m.	-15.2%
Free cash flow	n.m.	n.m.	n.m.	n.m.	n.m.	-47.2%
AEBITDA / share	n.m.	n.m.	n.m.	n.m.	n.m.	346%

Imprint / Disclaimer

First Berlin Equity Research

First Berlin Equity Research GmbH ist ein von der BaFin betreffend die Einhaltung der Pflichten des §85 Abs. 1 S. 1 WpHG, des Art. 20 Abs. 1 Marktmissbrauchsverordnung (MAR) und der Markets Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Durchführungsverordnung und der Markets in Financial Instruments Regulations (MiFIR) beaufsichtigtes Unternehmen.

First Berlin Equity Research GmbH is one of the companies monitored by BaFin with regard to its compliance with the requirements of Section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) Market Abuse Regulation (MAR) and Markets in Financial Instruments Directive (MiFID) II, Markets in Financial Instruments Directive (MiFID) II Commission Delegated Regulation and Markets in Financial Instruments Regulations (MiFIR).

Anschrift: First Berlin Equity Research GmbH Friedrichstr. 34 10117 Berlin Germany

Vertreten durch den Geschäftsführer: Martin Bailey

Telefon: +49 (0) 30-80 93 9 680 Fax: +49 (0) 30-80 93 9 687 E-Mail: <u>info@firstberlin.com</u>

Amtsgericht Berlin Charlottenburg HR B 103329 B UST-Id.: 251601797 Ggf. Inhaltlich Verantwortlicher gem. § 6 MDStV First Berlin Equity Research GmbH

Authored by: Ellis Acklin, Senior Analyst All publications of the last 12 months were authored by Ellis Acklin.

Company responsible for preparation: First Berlin Equity Research GmbH, Friedrichstraße 69, 10117 Berlin

The production of this recommendation was completed on 2 May 2024 at 10:33

Person responsible for forwarding or distributing this financial analysis: Martin Bailey

Copyright 2024 First Berlin Equity Research GmbH No part of this financial analysis may be copied, photocopied, duplicated or distributed in any form or media whatsoever without prior written permission from First Berlin Equity Research GmbH. First Berlin Equity Research GmbH shall be identified as the source in the case of quotations. Further information is available on request.

INFORMATION PURSUANT TO SECTION 85 (1) SENTENCE 1 OF THE GERMAN SECURITIES TRADING ACT [WPHG], TO ART. 20 (1) OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF APRIL 16, 2014, ON MARKET ABUSE (MARKET ABUSE REGULATION) AND TO ART. 37 OF COMMISSION DELEGATED REGULATION (EU) NO 2017/565 (MIFID) II.

First Berlin Equity Research GmbH (hereinafter referred to as: "First Berlin") prepares financial analyses while taking the relevant regulatory provisions, in particular section 85 (1) sentence 1 of the German Securities Trading Act [WpHG], art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) and art. 37 of Commission Delegated Regulation (EU) no. 2017/565 (MiFID II) into consideration. In the following First Berlin provides investors with information about the statutory provisions that are to be observed in the preparation of financial analyses.

CONFLICTS OF INTEREST

In accordance with art. 37 (1) of Commission Delegated Regulation (EU) no. 2017/565 (MiFID) II and art. 20 (1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse (market abuse regulation) investment firms which produce, or arrange for the production of, investment research that is intended or likely to be subsequently disseminated to clients of the firm or to the public, under their own responsibility or that of a member of their group, shall ensure the implementation of all the measures set forth in accordance with Article 34 (2) lit. (b) of Regulation (EU) 2017/565 in relation to the financial analysts involved in the production of the investment research and other relevant persons whose responsibilities or business interests may conflict with the interests of the persons to whom the investment research is disseminated. In accordance with art. 34 (3) of Regulation (EU) 2017/565 the procedures and measures referred to in paragraph 2 lit. (b) of such article shall be designed to ensure that relevant persons engaged in different business activities involvies at level of independence appropriate to the size and activities of the investment firm and of the group to which it belongs, and to the risk of damage to the interests of clients.

In addition, First Berlin shall pursuant to Article 5 of the Commission Delegated Regulation (EU) 2016/958 disclose in their recommendations all relationships and circumstances that may reasonably be expected to impair the objectivity of the financial analyses, including interests or conflicts of interest, on their part or on the part of any natural or legal person working for them under a contract, including a contract of employment, or otherwise, who was involved in producing financial analyses, concerning any financial instrument or the issuer to which the recommendation directly or indirectly relates.

With regard to the financial analyses of urban-gro, Inc. the following relationships and circumstances exist which may reasonably be expected to impair the objectivity of the financial analyses: The author, First Berlin, or a company associated with First Berlin reached an agreement with the urban-gro, Inc. for preparation of a financial analysis for which remuneration is owed.

Furthermore, First Berlin offers a range of services that go beyond the preparation of financial analyses. Although First Berlin strives to avoid conflicts of interest wherever possible, First Berlin may maintain the following relations with the analysed company, which in particular may constitute a potential conflict of interest:

- The author, First Berlin, or a company associated with First Berlin owns a net long or short position exceeding the threshold of 0.5 % of the total issued share capital of the analysed company;
- The author, First Berlin, or a company associated with First Berlin holds an interest of more than five percent in the share capital of the analysed company;

- The author, First Berlin, or a company associated with First Berlin provided investment banking or consulting services for the analysed company within the past twelve months for which remuneration was or was to be paid;
- The author, First Berlin, or a company associated with First Berlin reached an agreement with the analysed company for preparation of a financial analysis for which remuneration is owed;
- The author, First Berlin, or a company associated with First Berlin has other significant financial interests in the analysed company;

With regard to the financial analyses of urban-gro, Inc. the following of the aforementioned potential conflicts of interests or the potential conflicts of interest mentioned in Article 6 paragraph 1 of the Commission Delegated Regulation (EU) 2016/958 exist: The author, First Berlin, or a company associated with First Berlin reached an agreement with the urban-gro, Inc. for preparation of a financial analysis for which remuneration is owed.

In order to avoid and, if necessary, manage possible conflicts of interest both the author of the financial analysis and First Berlin shall be obliged to neither hold nor in any way trade the securities of the company analyzed. The remuneration of the author of the financial analysis stands in no direct or indirect connection with the recommendations or opinions represented in the financial analysis. Furthermore, the remuneration of the author of the financial analysis is neither coupled directly to financial transactions nor to stock exchange trading volume or asset management fees.

INFORMATION PURSUANT TO SECTION 64 OF THE GERMAN SECURITIES TRADING ACT [WPHG], DIRECTIVE 2014/65/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 15 MAY 2014 ON MARKETS IN FINANCIAL INSTRUMENTS AND AMENDING DIRECTIVE 2002/92/EC AND DIRECTIVE 2011/61/EU, ACCOMPANIED BY THE MARKETS IN FINANCIAL INSTRUMENTS REGULATION (MIFIR, REG. EU NO. 600/2014).

First Berlin notes that is has concluded a contract with the issuer to prepare financial analyses and is paid for that by the issuer. First Berlin makes the financial analysis simultaneously available for all interested security financial services companies. First Berlin thus believes that it fulfils the requirements of section 64 WpHG for minor non-monetary benefits.

PRICE TARGET DATES

Unless otherwise indicated, current prices refer to the closing prices of the previous trading day.

AGREEMENT WITH THE ANALYSED COMPANY AND MAINTENANCE OF OBJECTIVITY

The present financial analysis is based on the author's own knowledge and research. The author prepared this study without any direct or indirect influence exerted on the part of the analysed company. Parts of the financial analysis were possibly provided to the analysed company prior to publication in order to avoid inaccuracies in the representation of facts. However, no substantial changes were made at the request of the analysed company following any such provision.

ASSET VALUATION SYSTEM

First Berlin's system for asset valuation is divided into an asset recommendation and a risk assessment.

ASSET RECOMMENDATION

The recommendations determined in accordance with the share price trend anticipated by First Berlin in the respectively indicated investment period are as follows:

Category Current market capitalisation (in €)			2 > 2 billion	
		0 - 2 billion		
Strong Buy ¹	An expected favourable price trend of:	> 50%	> 30%	
Buy	An expected favourable price trend of:	> 25%	> 15%	
Add	An expected favourable price trend of:	0% to 25%	0% to 15%	
Reduce	An expected negative price trend of:	0% to -15%	0% to -10%	
Sell	An expected negative price trend of:	< -15%	< -10%	

¹ The expected price trend is in combination with sizable confidence in the quality and forecast security of management

Our recommendation system places each company into one of two market capitalisation categories. Category 1 companies have a market capitalisation of $\leq 0 - \leq 2$ billion, and Category 2 companies have a market capitalisation of $> \leq 2$ billion. The expected return thresholds underlying our recommendation system are lower for Category 2 companies than for Category 1 companies. This reflects the generally lower level of risk associated with higher market capitalisation companies.

RISK ASSESSMENT

The First Berlin categories for risk assessment are low, average, high and speculative. They are determined by ten factors: Corporate governance, quality of earnings, management strength, balance sheet and financial risk, competitive position, standard of financial disclosure, regulatory and political uncertainty, strength of brandname, market capitalisation and free float. These risk factors are incorporated into the First Berlin valuation models and are thus included in the target prices. First Berlin customers may request the models.

RECOMMENDATION & PRICE TARGET HISTORY

Report No.:	Date of publication			Price target	
Initial Report	27 June 2023	\$1.21	Buy	\$7.00	
21	Ļ	Ļ	Ļ	Ļ	
2	17 August 2023	\$1.11	Buy	\$6.40	
3	27 September 2023	\$1.40	Buy	\$6.40	
4	17 November 2023	\$1.18	Buy	\$4.70	
5	16 January 2024	\$1.47	Buy	\$4.70	
6	4 April 2024	\$1.91	Buy	\$4.30	
7	Today	\$1.86	Buy	\$4.30	

INVESTMENT HORIZON

Unless otherwise stated in the financial analysis, the ratings refer to an investment period of twelve months.

UPDATES

At the time of publication of this financial analysis it is not certain whether, when and on what occasion an update will be provided. In general First Berlin strives to review the financial analysis for its topicality and, if required, to update it in a very timely manner in connection with the reporting obligations of the analysed company or on the occasion of ad hoc notifications.

SUBJECT TO CHANGE

The opinions contained in the financial analysis reflect the assessment of the author on the day of publication of the financial analysis. The author of the financial analysis reserves the right to change such opinion without prior notification.

Legally required information regarding

- key sources of information in the preparation of this research report
- valuation methods and principles
- sensitivity of valuation parameters

can be accessed through the following internet link: https://firstberlin.com/disclaimer-english-link/

SUPERVISORY AUTHORITY: Bundesanstalt für Finanzdienstleistungsaufsicht (German Federal Financial Supervisory Authority) [BaFin], Graurheindorferstraße 108, 53117 Bonn and Marie-Curie-Straße 24-28, 60439 Frankfurt am Main

EXCLUSION OF LIABILITY (DISCLAIMER)

RELIABILITY OF INFORMATION AND SOURCES OF INFORMATION

The information contained in this study is based on sources considered by the author to be reliable. Comprehensive verification of the accuracy and completeness of information and the reliability of sources of information has neither been carried out by the author nor by First Berlin. As a result no warranty of any kind whatsoever shall be assumed for the accuracy and completeness of information and the reliability of sources of information nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the accuracy and completeness of information and the reliability of sources of information.

RELIABILITY OF ESTIMATES AND FORECASTS

The author of the financial analysis made estimates and forecasts to the best of the author's knowledge. These estimates and forecasts reflect the author's personal opinion and judgement. The premises for estimates and forecasts as well as the author's perspective on such premises are subject to constant change. Expectations with regard to the future performance of a financial instrument are the result of a measurement at a single point in time and may change at any time. The result of a financial analysis always describes only one possible future development – the one that is most probable from the perspective of the author's of a number of possible future developments.

Any and all market values or target prices indicated for the company analysed in this financial analysis may not be achieved due to various risk factors, including but not limited to market volatility, sector volatility, the actions of the analysed company, economic climate, failure to achieve earnings and/or sales forecasts, unavailability of complete and precise information and/or a subsequently occurring event which affects the underlying assumptions of the author and/or other sources on which the author relies in this document. Past performance is not an indicator of future results; past values cannot be carried over into the future.

Consequently, no warranty of any kind whatsoever shall be assumed for the accuracy of estimates and forecasts, and neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be liable for any direct or indirect damage incurred through reliance on the correctness of estimates and forecasts.

INFORMATION PURPOSES, NO RECOMMENDATION, SOLICITATION, NO OFFER FOR THE PURCHASE OF SECURITIES

The present financial analysis serves information purposes. It is intended to support institutional investors in making their own investment decisions; however in no way provide the investor with investment advice. Neither the author, nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall be considered to be acting as an investment advisor or portfolio manager vis-à-vis an investor. Each investor must form his own independent opinion with regard to the suitability of an investment in view of his own investment objectives, experience, tax situation, financial position and other circumstances.

The financial analysis does not represent a recommendation or solicitation and is not an offer for the purchase of the security specified in this financial analysis. Consequently, neither the author nor First Berlin, nor the person responsible for passing on or distributing the financial analysis shall as a result be liable for losses incurred through direct or indirect employment or use of any kind whatsoever of information or statements arising out of this financial analysis.

A decision concerning an investment in securities should take place on the basis of independent investment analyses and procedures as well as other studies including, but not limited to, information memoranda, sales or issuing prospectuses and not on the basis of this document.

NO ESTABLISHMENT OF CONTRACTUAL OBLIGATIONS

By taking note of this financial analysis the recipient neither becomes a customer of First Berlin, nor does First Berlin incur any contractual, quasi-contractual or pre-contractual obligations and/or responsibilities toward the recipient. In particular no information contract shall be established between First Berlin and the recipient of this information.

NO OBLIGATION TO UPDATE

First Berlin, the author and/or the person responsible for passing on or distributing the financial analysis shall not be obliged to update the financial analysis. Investors must keep themselves informed about the current course of business and any changes in the current course of business of the analysed company.

DUPLICATION

Dispatch or duplication of this document is not permitted without the prior written consent of First Berlin.

SEVERABILITY

Should any provision of this disclaimer prove to be illegal, invalid or unenforceable under the respectively applicable law, then such provision shall be treated as if it were not an integral component of this disclaimer; in no way shall it affect the legality, validity or enforceability of the remaining provisions.

APPLICABLE LAW, PLACE OF JURISDICTION

The preparation of this financial analysis shall be subject to the law obtaining in the Federal Republic of Germany. The place of jurisdiction for any disputes shall be Berlin (Germany).

NOTICE OF DISCLAIMER

By taking note of this financial analysis the recipient confirms the binding nature of the above explanations.

By using this document or relying on it in any manner whatsoever the recipient accepts the above restrictions as binding for the recipient.

QUALIFIED INSTITUTIONAL INVESTORS

First Berlin financial analyses are intended exclusively for qualified institutional investors.

This report is not intended for distribution in the USA and/or Canada.